Marc Cote is an entrepreneur, a business/executive coach and area representative with FocalPoint Business Coaching. Marc is also a former corporate executive and leverages his coaching program materials and his 30 years of business experience to help entrepreneur, business leaders and executives raise money, improve their effectiveness, develop their people and enhance the performance of their teams and companies. Marc is the son of a second-generation business owner with a deep-seated passion for business and helping others succeed. He was also a co-founder and the COO of Accellient Partners LLC, a drug development consulting firm, Synchroneuron Inc, a venture-backed biotech where he helped raise over $25M and Ternus Pharma, Inc, a seed-stage start-up pharma company. Marc continues to focus much of his coaching practice supporting those in the life sciences arena. Marc was also previously the COO of Aptuit Consulting, a global biotech practice where he was responsible for managing all operating, financial & business development activities. Prior to Aptuit, Marc was with Dunkin’ Brands and had vice president roles across multiple functions. Marc started his career in the Entrepreneurial Services Group at EY, he received a BS in Accountancy from Bentley College, summa cum laude, and earned his CPA certificate in MA where he was a licensed CPA for 17 years Marc is a member of Boston Harbor Angels and Sky Ventures where he is an active investor and also maintains a Board role on select portfolio companies. Marc is also a Co-Chair of Mass Bio's Entrepreneur University and the Boston Chapter of The Financial Executives Networking Group.

John Hession is a Partner at Morse, Barnes-Brown & Pendleton, and a member of the firm’s Corporate, Venture Capital and Life Sciences practice groups. Previously, John was a co-founder of Cooley LLP's Boston office, and served as the Managing Partner of the Cooley Boston office for its first several years of operation, helping to steer and grow the Boston office from ten to seventy-plus professionals and staff. For the last thirty-five years, John has represented emerging-growth companies, as both a legal and business advisor, principally in the life sciences, medical device, hardware, software and software services sectors, as well as angels and venture capital funds in the investment process. John is also angel investor in emerging companies. John’s practice includes both start-up, emerging growth and later-stage company work, where he serves as outside general counsel. This work includes corporate governance; equity-based compensation strategies; mergers and acquisitions (representing buyers and sellers); and strategic alliances, corporate partnering, joint ventures, collaboration and development projects, and other strategic alliances involving technology transfers; as well venture capital and angel financings of companies in these sectors, representing principally companies and their management teams. John has structured and negotiated more than 400 debt and equity financings, ranging in scale from $500,000 to $250 million, and more than 350 acquisitions ranging in size from $1.0 million to $4.2 billion. During his thirty-five year career, John has represented more than 400 companies from the earliest stages of development, from cradle to culmination, from inception to liquidity (including public offering and acquisitions). John has won a number of industry awards during his career, including Best Lawyers in America, IP Stars (Managing Intellectual Property), Lawdragon 500 Leading Deal Makers, a Massachusetts Super Lawyer, and Best Lawyers in New England.

Molly Hoult is a Senior Principal with Promidian where she helps life science companies build value by meeting market needs better than competitors. She digs deep into market and competitive dynamics to determine how best to develop a product, enter a market, and expand into new areas to accelerate growth. Delivering actionable recommendations to management, boards of directors, and investors, Molly has been a strategic partner to biopharma, diagnostics, and medical device companies of all sizes for over 15 years. Her experience spans corporate and commercial strategy, new product planning, market research, business and corporate development, across major therapeutic areas in US and European markets. Before joining Promidian, Molly spent a decade as Senior Vice President at Fletcher Spaght, Inc., providing strategy consulting to healthcare companies. Molly spent another decade in senior Marketing and Business Development roles at Blue Heron Biotechnology, XCyte Therapies, ZymoGenetics (now part of Bristol-Myers Squibb) and NeoPath (now part of BD Diagnostics). Molly holds an MBA from Stanford Graduate School of Business, where she was an Arjay Miller Scholar, and a bachelor of arts with honors in biology and a minor in environmental studies from Dartmouth College.

Gael O’Brien is a catalyst in leaders leading with purpose and impact through clarity, presence and connection. She is an executive coach, culture coach, speech coach and leadership columnist with an extensive corporate background. She is also a speaker at international and national conferences, universities and business events. Gael was recruited to Mitsubishi Motor Manufacturing of America to help lead a model workplace initiative and culture change. She was promoted to vice president at Mitsubishi Motors North America where she led teams in four locations and the corporate foundation and was also director of marketing at a Price Waterhouse office. Gael is founder and president of Strategic Opportunities Group, a columnist for Business Ethics Magazine, the creator of the Ethics Coach column for Entrepreneur Magazine and publisher of The Week in Ethics blog. She is a Kallman Executive Fellow at the Hoffman Center for Business Ethics at Bentley University and a Senior Fellow Social Innovation at the Lewis Institute at Babson College.